About This Dosing Guide

This guide provides a detailed overview of the dosing principles for Olumiant (baricitinib) across its approved indications. It is intended to supplement the Olumiant (baricitinib) Dose Calculator by explaining the clinical factors that influence dose selection, such as renal and hepatic function, concomitant medications, and the specific condition being treated.

Outputs Explained

When using the associated calculator, the primary output is the recommended daily oral dose of baricitinib in milligrams. The tool also provides essential context for the recommendation, including:

• Calculated Renal Function: The estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) value used for dose adjustment.
• Dosing Rationale: A clear explanation for any dose modifications, such as adjustments for moderate renal impairment or the use of an OAT3 inhibitor.
• Critical Warnings: Alerts for situations where baricitinib is not recommended, such as in severe renal or hepatic impairment.

How to Use the Calculator

To determine the appropriate baricitinib dose, the calculator requires several key patient parameters. Ensure you have the following information available:

• Indication: Select Rheumatoid Arthritis (RA), Alopecia Areata (AA), or COVID-19.
• Patient Demographics: Age, weight, and sex are required for accurate renal function calculation.
• Renal Function: Provide a recent serum creatinine (SCr) value to calculate eGFR/CrCl, or manually enter a known value.
• Hepatic Function: Specify the degree of hepatic impairment (Child-Pugh class).
• Concomitant Medications: Indicate if the patient is taking a strong OAT3 inhibitor like probenecid.

Dosing Overview

Baricitinib dosing is tailored to the indication and adjusted based on patient-specific factors. The standard recommended doses are:

• Rheumatoid Arthritis (RA): The recommended dose is 2 mg once daily.
• Alopecia Areata (AA): The recommended dose is 2 mg once daily, which may be increased to 4 mg once daily if the response to treatment is not adequate. The 4 mg dose can be considered for patients without risk factors for thromboembolism, MACE, or malignancy.
• COVID-19 (Hospitalized Adults): The recommended dose is 4 mg once daily for 14 days or until hospital discharge, whichever comes first.

Dose Adjustments:

• Renal Impairment: For RA and AA, the dose is halved (e.g., 2 mg becomes 1 mg) if eGFR is 30 to <60 mL/min. Use is not recommended if eGFR is <30 mL/min. For COVID-19, the dose is adjusted for moderate and severe impairment.
• Hepatic Impairment: No dose adjustment is needed for mild or moderate hepatic impairment. Use is not recommended in patients with severe hepatic impairment (Child-Pugh C).
• OAT3 Inhibitors: If co-administered with a strong OAT3 inhibitor (e.g., probenecid), the recommended baricitinib dose should be halved.

Switching Therapies

There is limited information on switching between Janus kinase (JAK) inhibitors or from biologic DMARDs to baricitinib. It is generally not recommended to use baricitinib in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine and cyclosporine. Always consult the full prescribing information and relevant clinical guidelines when considering a switch in therapy.

Missed Dose

If a dose of Olumiant is missed, the patient should be advised to take it as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their normal dosing schedule. Patients should not take two doses to make up for a missed dose.

Safety Alerts

Baricitinib carries important safety warnings that clinicians must consider before and during treatment.

Frequently Asked Questions (FAQ)

1. Why does the calculator require the patient's sex?
Sex is a variable in both the CKD-EPI (for eGFR) and Cockcroft-Gault (for CrCl) equations used to estimate renal function, which is critical for dose adjustments.

2. What is a strong OAT3 inhibitor and why does it matter?
A strong Organic Anion Transporter 3 (OAT3) inhibitor, such as probenecid, can significantly increase the concentration of baricitinib in the blood. To avoid potential toxicity, the baricitinib dose must be reduced by half when taken with these medications.

3. What is the recommended dose if a patient's eGFR is 25 mL/min?
For Rheumatoid Arthritis or Alopecia Areata, Olumiant is not recommended for patients with an eGFR less than 30 mL/min. For COVID-19, the dose would be reduced to 1 mg daily.

4. How does the calculator handle severe liver disease (Child-Pugh C)?
The tool will issue a warning that Olumiant is not recommended for patients with severe hepatic impairment, as its safety and efficacy have not been studied in this population.

5. Can I use the 4 mg dose for a patient with Rheumatoid Arthritis?
No, the approved and recommended dose for RA is 2 mg once daily. The 4 mg dose is only an option for specific patients with Alopecia Areata.

6. Why are there options for CKD-EPI and Cockcroft-Gault?
Both are common methods for estimating kidney function. The prescribing information for baricitinib bases recommendations on eGFR, making CKD-EPI the preferred method. Cockcroft-Gault (CrCl) is provided as an alternative clinical standard.

7. Is there a dose adjustment for body weight?
No, baricitinib dosing is not based on body weight. Weight is only used as a variable in the Cockcroft-Gault equation to estimate creatinine clearance.

8. Does this guide replace a consultation with a healthcare professional?
Absolutely not. This information and the associated calculator are educational tools and are not a substitute for clinical judgment. All treatment decisions must be made by a qualified healthcare provider.

9. Is a dose adjustment required for elderly patients?
No dose adjustment is required based on age alone. However, since renal function often declines with age, an age-related decrease in eGFR may necessitate a dose adjustment.

References

1. OLUMIANT (baricitinib) US Prescribing Information. Eli Lilly and Company.
2. Olumiant (baricitinib) European Public Assessment Report (EPAR). European Medicines Agency.
3. Olumiant for Healthcare Professionals. Eli Lilly and Company.
4. COVID-19 Treatment Guidelines: Baricitinib. National Institutes of Health (NIH).